Literature DB >> 9701523

Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection.

B E Schenk1, E J Kuipers, E C Klinkenberg-Knol, E Bloemena, G F Nelis, H P Festen, E H Jansen, I Biemond, C B Lamers, S G Meuwissen.   

Abstract

AIM: elucidate the mechanisms that lead to severe hypergastrinaemia during long-term omeprazole therapy for gastro-oesophageal reflux disease (GERD). PATIENTS AND METHODS: A total of 26 GERD patients were studied during omeprazole maintenance therapy. Twelve patients with severe hypergastrinaemia (gastrin > 400 ng/L) were compared with 14 control patients (gastrin < 300 ng/L). Helicobacter pylori serology and a laboratory screen were obtained in all patients. Gastric emptying was scored by the evidence of food remnants upon endoscopy 12 h after a standardized meal. Gastric antrum and corpus biopsies were analysed for histological parameters, as well as somatostatin and gastrin concentrations. All patients underwent a meal-stimulated gastrin test and the hypergastrinaemia patients also underwent a vagal nerve integrity assessment by pancreatic polypeptide testing (PPT).
RESULTS: Severe hypergastrinaemia patients had a longer duration of treatment (80 vs. 55 months; P = 0.047) and were characterized by a higher prevalence of H. pylori infection (9/12 vs. 2/14, P = 0.004), corpus mucosal inflammation and atrophic gastritis (P < 0.04). This was reflected in lower serum pepsinogen A concentrations (mean +/- S.E.M. 53.6 +/- 17.9 vs. 137 +/- 16.0 mg/L, P = 0.03), pepsinogen A/C ratio (1.8 +/- 0.3 vs. 4.1 +/- 0.6, P = 0.005) and mucosal somatostatin concentrations (2.75 +/- 0.60 vs. 4.48 +/- 1.08 mg/g protein, P = 0.038). Two patients in the hypergastrinaemia group had signs of delayed gastric emptying, but none in the normogastrinaemia group did (P = N.S.). In addition, both groups had a normal meal-stimulated gastrin response.
CONCLUSION: Severe hypergastrinaemia during omeprazole maintenance therapy for GERD is associated with the duration of therapy and H. pylori infection, but not with abnormalities of gastric emptying or vagal nerve integrity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701523     DOI: 10.1046/j.1365-2036.1998.00349.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

1.  Helicobacter pylori infection and gastrointestinal hormones:a review.

Authors:  Xiang-Qian Huang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

3.  Hypergastrinaemia in patients infected with Helicobacter pylori treated with proton pump inhibitors.

Authors:  H L Waldum
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

4.  Proton pump inhibitors and gastric neoplasia.

Authors:  E J Kuipers
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 5.  Effects of proton pump inhibitors on gastric emptying: a systematic review.

Authors:  Masaki Sanaka; Takatsugu Yamamoto; Yasushi Kuyama
Journal:  Dig Dis Sci       Date:  2009-12-10       Impact factor: 3.199

Review 6.  Antiulcer drugs and gastric cancer.

Authors:  Helge L Waldum; Bjørn Gustafsson; Reidar Fossmark; Gunnar Qvigstad
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

7.  Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection.

Authors:  Yuichi Sato; Mitsuya Iwafuchi; Jun-Ichi Ueki; Akira Yoshimura; Tsutomu Mochizuki; Hirotaka Motoyama; Kazuhito Sugimura; Terasu Honma; Rintaro Narisawa; Takafumi Ichida; Hitoshi Asakura; D H Van Thiel
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

8.  Delivery of radiofrequency energy to the gastroesophageal junction (Stretta procedure) for the treatment of gastroesophageal reflux disease.

Authors:  L Cipolletta; G Rotondano; L Dughera; A Repici; M A Bianco; C De Angelis; A M Vingiani; E Battaglia
Journal:  Surg Endosc       Date:  2005-05-03       Impact factor: 4.584

Review 9.  The dynamics of gastritis.

Authors:  E J Kuipers; T A Grool
Journal:  Curr Gastroenterol Rep       Date:  2001-12

10.  Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.

Authors:  E J Kuipers; G F Nelis; E C Klinkenberg-Knol; P Snel; D Goldfain; J J Kolkman; H P M Festen; J Dent; P Zeitoun; N Havu; M Lamm; A Walan
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.